Literature DB >> 30689690

RE: "MEASUREMENT OF VACCINE DIRECT EFFECTS UNDER THE TEST-NEGATIVE DESIGN".

Natalie E Dean1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30689690      PMCID： PMC6438809          DOI： 10.1093/aje/kwz019

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN： 0002-9262            Impact factor:   4.897


× No keyword cloud information.
  3 in total

1.  Is it necessary to adjust for calendar time in a test negative design?: Responding to: Jackson ML, Nelson JC. The test negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31(April (17)):2165-8.

Authors:  Peter Jacoby; Heath Kelly
Journal:  Vaccine       Date:  2013-09-07       Impact factor: 3.641

2.  Measurement of Vaccine Direct Effects Under the Test-Negative Design.

Authors:  Joseph A Lewnard; Christine Tedijanto; Benjamin J Cowling; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

3.  The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials.

Authors:  G De Serres; D M Skowronski; X W Wu; C S Ambrose
Journal:  Euro Surveill       Date:  2013-09-12
  3 in total
  6 in total

1.  THE AUTHORS REPLY.

Authors:  Joseph A Lewnard; Christine Tedijanto; Benjamin J Cowling; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2019-04-01       Impact factor: 4.897

2.  Temporal Confounding in the Test-Negative Design.

Authors:  Natalie E Dean; M Elizabeth Halloran; Ira M Longini
Journal:  Am J Epidemiol       Date:  2020-11-02       Impact factor: 4.897

3.  Potential test-negative design study bias in outbreak settings: application to Ebola vaccination in Democratic Republic of Congo.

Authors:  Carl A B Pearson; W John Edmunds; Thomas J Hladish; Rosalind M Eggo
Journal:  Int J Epidemiol       Date:  2022-02-18       Impact factor: 7.196

4.  Surveillance of COVID-19 vaccine effectiveness - a real-time case-control study in southern Sweden.

Authors:  Jonas Björk; Carl Bonander; Mahnaz Moghaddassi; Magnus Rasmussen; Ulf Malmqvist; Fredrik Kahn; Malin Inghammar
Journal:  Epidemiol Infect       Date:  2022-03-02       Impact factor: 2.451

5.  Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022.

Authors:  Fredrik Kahn; Carl Bonander; Mahnaz Moghaddassi; Magnus Rasmussen; Ulf Malmqvist; Malin Inghammar; Jonas Björk
Journal:  Euro Surveill       Date:  2022-03

6.  COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022.

Authors:  Jonas Björk; Carl Bonander; Mahnaz Moghaddassi; Magnus Rasmussen; Ulf Malmqvist; Malin Inghammar; Fredrik Kahn
Journal:  Euro Surveill       Date:  2022-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.